Monitoring Signal Transduction in Cancer: Tyrosine Kinase Gene Expression ProfilingHeinz-Ulrich G. Weiera, Horst F. Zitzelsbergerb, H.-Ben Hsieha, Melita V. Suna, Mariwil Wongc, Robert A. Lerscha, Paul Yaswena, Jan Smidab, Christine Kuschnickb, and Orlo H. Clarkca Life Sciences Division, University of California, E.O. Lawrence Berkeley National Laboratory, Berkeley, California b Arbeitsgruppe Zytogenetik, gsf-Forschungszentrum fuer Umwelt und Gesundheit, Neuherberg, Germany c Department of Surgery, University of California, San Francisco, California Correspondence to: Heinz-Ulrich G. Weier, Life Sciences Division, Lawrence Berkeley National Laboratory, U. of California, 1 Cyclotron Road, MS 74157, Berkeley, CA 94720. E-mail: ugweier@lbl.gov
Abnormal expression of tyrosine kinase (TK) genes is common in tumors, in which it is believed to alter cell growth and response to external stimuli such as growth factors and hormones. Although the etiology and pathogenesis of carcinomas of the thyroid or breast remain unclear, there is evidence that the expression of TK genes, such as receptor tyrosine kinases, or mitogen-activated protein kinases, is dysregulated in these tumors, and that overexpression of particular TK genes due to gene amplification, changes in gene regulation, or structural alterations leads to oncogenic transformation of epithelial cells. We developed a rapid scheme to measure semiquantitatively the expression levels of 50100 TK genes. Our assay is based on RT-PCR with mixed based primers that anneal to conserved regions in the catalytic domain of TK genes to generate gene-specific fragments. PCR products are then labeled by random priming and hybridized to DNA microarrays carrying known TK gene targets. Inclusion of differently labeled fragments from reference or normal cells allows identification of TK genes that show altered expression levels during malignant transformation or tumor progression. Examples demonstrate how this innovative assay might help to define new markers for tumor progression and potential targets for disease intervention. (J Histochem Cytochem 49:673-674, 2001) Key Words: tyrosine kinase, tumors, RT-PCR, genes
Because the malignant transformation of epithelial cells and progression of carcinomas are accompanied by changes in the expression of receptor and cytosolic tyrosine kinase (TK) genes, we set out to develop an innovative DNA microarray-based assay to simultaneously determine the relative expression level of 50100 TK genes using just a few cells.A number of studies have shown that tumor development is accompanied by at least two changes: (a) a change in the way cells interact with their environment via membrane-bound receptors, and (b) a change in how signals originating from these receptors are transduced from the cell membrane to the cytoplasm and the nucleus. Among the hundreds of genes involved in receptor-mediated signal transduction, only a few are aberrantly expressed in tumors. A major motif in signal transduction is the selective phosphorylation and dephosphorylation of tyrosine residues in protein factors involved in signal processing. Proteins that phosphorylate tyrosine residues are products of genes belonging to the family of TK genes. The number of known TK genes has grown steadily in recent years, and the temporal and tissue-specific expression of
Various protein factors can be mis-expressed and, in combination with other events, might constitute one of several factors leading to the onset and/or progression of cancer. Factors including cell cycle-specific enzymes, hormone receptors, and peptide growth factors have been reported as having prognostic significance in some cases of prostate cancer. Overexpression of particular receptor TK genes such as the insulin-like growth factor receptors (IGF-IRs), the epidermal growth factor receptor (EGFR or erb B) family of receptors, focal adhesion kinase (FAK), or the proto-oncogenes ret and Nyk/mer have been shown to correlate with progression to a more malignant phenotype in a variety of tumors (
Our project targets the development of a novel assay format that enables us to determine the level of expression of many different genes. A rapid assay uses DNA microarrays carrying small amounts of individual TK gene-specific targets to simultaneously determine the expression level of up to 100 TK genes using a small number of cells. We cloned and characterized TK genes expressed in thyroid cancers and in seven different breast cancer cell lines. Using mixed-base oligonucleotides specific for conserved domains in the catalytic domains of TK genes, our PCR assays amplified
Presented in part at the Joint Meeting of the Histochemical Society and the International Society for Analytical and Molecular Morphology, Santa Fe, NM, February 27, 2001.
Supported by a grant from the Director, Office of Science, Office of Biological and Environmental Research, US Department of Energy, under contract DE-AC03-76SF00098, by the Cancer Research Foundation of America and grants from the Cancer Research Programs, United States Army Medical Research and Materiel Command, US Department of the Army (DAMD17-99-1, PC991359). Received for publication November 30, 2000; accepted February 16, 2001.
Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick I, Kursh ED, Pretlow TP, Pretlow TG (1998) Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate. J Natl Cancer Inst 90:519-523 Jhiang SM, Mazzaferri EL (1994) The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 123:331-337[Medline] Ling L, Kung HJ (1995) Mitogenic signals, transforming potential of Nyk, a newly identified neural cell adhesion molecule-related receptor tyrosine kinase. Mol Cell Biol 15:6582-6592[Abstract] Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG (1995) MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions, reduced estrogen-dependence, tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117[Medline]
Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, Willard D, Luther M, Rodriguez M, Berman J, Gilmer TM (1994) Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci USA 91:83-87
Resnik JL, Reichart DB, Huey K, Webster NJ, Seely BL (1998) Elevated insulin-like growth factor I receptor autophosphorylation, kinase activity in human breast cancer. Cancer Res 58:1159-1164 Sozzi G, Bongarzone I, Miozzo M, Cariani CT, Mondellini P, Calderone C, Pilotti S, Pierotti MA, Della Porta G (1992) Cytogenetic, molecular genetic characterization of papillary thyroid carcinomas. Genes Chromosomes Cancer 5:212-218[Medline] Tse C, Brault D, Etienne J (1997) Current aspects of the evaluation of the ERBB2 activation in breast cancer. Therapeutic perspectives. Ann Biol Clin 55:545-554
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||